The director's concentrated open-market selling without a 10b5-1 plan is a material bearish signal for a clinical-stage biotech. Monitor for any upcoming corporate events (data readouts, financing, or partnership news) that may have prompted the selling. The next 8-K or press release should be scrutinized for negative developments.
Price Chart
Executive Summary
Director George M. Jenkins sold a total of ~27,500 shares worth ~$4.17M in open-market sales over three trading days (Sep 11-15), while COO Kathleen Goin sold ~1,700 shares worth ~$251K on Sep 16. The combined insider selling of ~$4.4M represents roughly 1.3% of PVLA's ~$326M market cap, a significant cluster of open-market sales by a director with no indicated 10b5-1 plan. This is a bearish signal for a clinical-stage biotech, as the director's concentrated selling is not liquidity-driven (no plan, no tax withholding).
Key Financial Metrics
Key Facts
- Director George M. Jenkins sold ~27,500 shares in open-market sales totaling ~$4.17M over Sep 11-15.
- COO Kathleen Goin sold ~1,700 shares in open-market sale totaling ~$251K on Sep 16.
- Total insider selling of ~$4.4M represents ~1.3% of PVLA's market cap (~$326M).
- No 10b5-1 plan indicated for any of the sales.
- Jenkins' sales were concentrated across three days with no regular pattern suggesting a pre-arranged plan.
Financial Impact
Director sold ~$4.17M in open-market shares (1.3% of market cap); COO sold ~$251K.
Risk Factors
- Director selling may signal adverse clinical data or financing concerns.
- COO selling adds to the bearish signal, though smaller in magnitude.
- Clinical-stage biotechs are highly sensitive to insider selling patterns.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PVLA-1789797884841 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | Insider Cluster | $125.10 | awaiting T+60 | — | $131.07 (+4.77%) |
Oct 15, 2026 12d ago | Press Release | $127.34 | awaiting T+60 | — | $131.07 (+2.93%) |
Oct 13, 2026 13d ago | 144 | $122.58 | awaiting T+60 | — | $131.07 (+6.93%) |
Sep 18, 2026 5w ago | Insider Cluster | $153.41 | awaiting T+60 | — | $131.07 (+14.56%) |
Sep 2, 2026 7w ago | 144 | $155.47 | awaiting T+60 | — | $131.07 (−15.69%) |
Aug 9, 2026 11w ago | Institutional Cluster | $152.22 | awaiting T+60 | — | $131.07 (−13.89%) |
Aug 4, 2026 12w ago | 8-K | $151.99 | awaiting T+60 | — | $131.07 (−13.76%) |
Jul 30, 2026 12w ago | Press Release | $150.19 $125.10 | ▼ −16.71% | ▼ −19.17% | $131.07 (−12.73%) |
Jul 28, 2026 13w ago | Press Release | $142.84 $126.58 | ▼ −11.38% | ▼ −15.73% | $131.07 (−8.24%) |
Jun 30, 2026 17w ago | 8-K | $152.82 $149.56 | ▼ −2.13% | ▼ −5.70% | $131.07 (−14.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers